Individuals infected with SARS-CoV-2 or influenza viruses
Care Setting
Acute care and research settings focusing on viral respiratory infections
Key Highlights
COVID-19 severity is influenced by host genetics involving interferon and inflammatory pathways, distinct from influenza.
COVID-19 exhibits a thrombo-inflammatory phenotype with pulmonary microthrombosis and endotheliopathy more frequently than influenza.
Multi-omics and explainable AI reveal conserved early interferon responses across viruses but COVID-19-specific persistent AP-1/MAPK activation and coagulation involvement.
Guideline-Based Recommendations
Diagnosis
Utilize genetic and multi-omic profiling to distinguish COVID-19 from influenza based on host immune response signatures.
Consider differential activation of interferon-stimulated genes and inflammatory cytokines in diagnostic assessments.
Management
Target host-directed interventions focusing on timing of interferon augmentation in COVID-19.
Modulate IL-6 inflammatory axis and apply endothelial protective and antithrombotic strategies in severe COVID-19 cases.
Monitoring & Follow-up
Monitor inflammatory cytokines (IL-6, IL-1, TNF) and coagulation markers to assess disease progression and thrombo-inflammatory status.
Track lymphocyte counts and interferon response dynamics to evaluate immune dysregulation.
Risks
Recognize increased risk of pulmonary microthrombosis and endotheliopathy in COVID-19 compared to influenza.
Be aware of maladaptive myeloid responses and lymphopenia contributing to severe COVID-19 outcomes.
Patient & Prescribing Data
Patients with confirmed COVID-19 or influenza infection
Genetically anchored multi-omic data support prioritizing host-directed therapies targeting interferon pathways, IL-6 signaling, and coagulation/endothelial dysfunction in COVID-19 management.
Clinical Best Practices
Integrate genetic risk profiling with multi-omic immune signatures to personalize treatment strategies.
Employ explainable AI models to differentiate viral infection types and guide targeted interventions.
Focus on early modulation of interferon responses and control of hyperinflammation to improve COVID-19 outcomes.
